Despite lower price of generic imatinib, overall costs for chronic myeloid leukemia remain high

ORLANDO — The price of generic imatinib has decreased substantially in the United States over the past 2 years, according to a speaker at ASH Annual Meeting and Exposition. The decline comes after steep increases in the price of the branded drug, which transformed treatment of chronic myeloid leukemia, and several years of expensive generic options.

Read the full article here

Related Articles